Jubilant Pharmova Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Jubilant Pharmova
Jubilant Pharmova Business Model Canvas: Downloadable Strategic Blueprint
Unlock the full strategic blueprint behind Jubilant Pharmova with our in-depth Business Model Canvas—detailing value propositions, revenue streams, partnerships, and cost structure to reveal how the company scales and sustains competitive advantage; ideal for investors, analysts, and entrepreneurs seeking actionable, ready-to-use insights. Download the complete Word and Excel canvas to benchmark, strategize, or present with confidence.
Partnerships
Strategic Nuclear Pharmacy Networks
Jubilant Pharmova relies on a network of 120+ nuclear pharmacies across North America to ensure timely delivery of time-sensitive radiopharmaceuticals, enabling same‑day compounding and distribution to 1,200+ hospitals and clinics. By year‑end 2025 these alliances supported rollout of five new PET and three new SPECT agents, boosting radiopharma revenues by an estimated 18% versus 2024.
Collaborative Research Institutions
Jubilant Pharmova partners with top academic centers and biotech firms to co-develop oncology and neurology drug candidates and radio-delivery systems, cutting early-stage discovery costs by ~40% versus solo R&D; in 2024 these collaborations supported a pipeline of 12 radiopharma programs and helped sustain R&D spend at INR 1.2 billion while targeting 30–40% higher clinical-readiness rates.
Supply Chain and Isotope Providers
Jubilant Pharmova locks long-term supply contracts with global reactor operators and processors for Molybdenum-99 and Lutetium-177, covering ~70–80% of projected 2025 demand to hedge shortages and price swings; these deals cut input-cost volatility, given Mo-99 spot swings of ±25% in 2023–24.
Global Distribution and Logistics Partners
Jubilant Pharmova uses specialized third-party cold-chain logistics for its allergy and sterile injectable segments, ensuring temperature-controlled delivery to Europe and Asia and supporting 2024 export growth—international revenues were ~INR 2,350 crore (≈USD 280M) in FY2024, with cold-chain exports up ~18% year-on-year.
- Third-party cold-chain providers
- Targets Europe and Asia markets
- Maintains strict temperature control
- Enables scaling without fleet capex
- Cold-chain exports +18% YoY (FY2024)
Regulatory and Quality Compliance Consultants
Working with FDA, EMA and other regulatory experts lets Jubilant Pharmova keep its Indian and North American plants aligned with evolving GMP; in 2024 the company reported 0 major compliance observations across its CRO and manufacturing audits, cutting average approval time for ANDAs and MAs by an estimated 18%.
Continuous consultant engagement helped accelerate filings for 12 new generic and 4 branded submissions in 2024, improving time-to-market and protecting annual revenue streams of roughly USD 55–65 million tied to those launches.
- 0 major audit observations (2024)
- 18% faster approvals (estimated)
- 16 total filings accelerated (2024)
- USD 55–65M projected revenue from accelerated launches
Jubilant Pharmova secures Mo‑99/Lu‑177 supply, 120+ pharmacies—driving +18% 2025 rev
Jubilant Pharmova secures 120+ North American nuclear pharmacies, long‑term Mo‑99/Lu‑177 supply (covering 70–80% 2025 demand), and cold‑chain logistics, supporting same‑day radiopharma delivery to 1,200+ sites and driving an estimated +18% radiopharma revenue growth in 2025.
| Partnership | Key metric | 2024/2025 impact |
|---|---|---|
| Nuclear pharmacies | 120+ | 1,200+ sites served |
| Reactor supply | 70–80% demand cover | Reduces ±25% spot volatility |
| Cold‑chain logistics | Exports +18% YoY | INR 2,350 cr international rev (FY2024) |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Jubilant Pharmova mapping its nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—reflecting its pharma manufacturing, contract research/CMO services, and specialty chemistries focus.
Customizable Excel Spreadsheet
High-level view of Jubilant Pharmova’s business model with editable cells to quickly pinpoint value drivers across pharmaceuticals and contract services.
Activities
Radiopharmaceutical Manufacturing and Innovation
Jubilant Pharmova manufactures high-precision diagnostic and therapeutic radiochemicals for nuclear medicine, running GMP cleanrooms and hot labs to ensure >99.5% radiochemical purity and compliance with AERB/US FDA standards; in FY2024 radiopharma revenue was ~INR 1,150 crore (about USD 140m). By late 2025 the company is scaling therapeutic isotope capacity—adding ~30% alpha-emitter output (targeting 100+ patient doses/month) to meet rising targeted alpha therapy demand.
Sterile Injectable Contract Manufacturing
Jubilant Pharmova provides high-end contract manufacturing for complex sterile injectables, serving global pharma with aseptic filling and lyophilization across cGMP facilities; sterile injectables contributed about 38% of Pharma segment revenue in FY2024 (₹1,120 crore of ₹2,950 crore). The company invests in capacity upgrades and process optimization, cutting cycle times by ~18% and improving batch yields to 96% for key biologics to meet high-volume client SLAs.
Drug Discovery and Development Services
The CRDMO wing runs medicinal chemistry, structural biology, and preclinical programs to find drug candidates for external biotech clients, generating high-margin services that accounted for roughly 28% of Jubilant Pharmova’s FY2024 service revenue (about INR 320 crore). These R&D-led services deepen client ties and supported a 12% CAGR in contract revenue from 2021–2024, reinforcing long-term, repeat-business pipelines.
Allergy Immunotherapy Production
Quality Control and Regulatory Submissions
Jubilant Pharmova performs continuous monitoring of manufacturing to ensure each batch meets international safety and efficacy standards, with in-house labs testing raw materials, in-process samples, and finished products; in 2024 the company reported CAPA closure rate of 92% and invested ~INR 120 crore in quality infrastructure.
It maintains regulatory documentation for ANDAs (Abbreviated New Drug Applications) and other filings, supporting 35+ active ANDAs and 8 US FDA-approved facilities as of Q4 2024.
- Continuous monitoring across production lines
- Lab testing: raw, in-process, finished goods
- 2024 CAPA closure rate 92%
- INR 120 crore quality capex (2024)
- 35+ active ANDAs; 8 US FDA sites (Q4 2024)
Jubilant Pharmova: FY24 INR 2,390cr pharma mix, 92% CAPA, ₹120cr quality capex, 8 FDA sites
Jubilant Pharmova runs GMP radiopharma, sterile injectables, CRDMO and allergy vaccine manufacturing, with FY2024 radiopharma ~INR 1,150 crore, sterile injectables ~INR 1,120 crore (38% of Pharma), CRDMO services ~INR 320 crore (28% of services), allergy ~INR 120 crore; CAPA closure 92%, ₹120 crore quality capex (2024), 35+ ANDAs, 8 US FDA sites (Q4 2024).
| Activity | FY2024 |
|---|---|
| Radiopharma | ~INR 1,150 cr |
| Sterile injectables | ~INR 1,120 cr |
| CRDMO services | ~INR 320 cr |
| Allergy | ~INR 120 cr |
| Quality | CAPA 92%, ₹120 cr capex |
| Regulatory | 35+ ANDAs; 8 US FDA sites |
Full Document Unlocks After Purchase
Business Model Canvas
The document you're previewing is the actual Jubilant Pharmova Business Model Canvas—not a mockup or sample—and reflects the exact content you will receive after purchase.
When you complete your order, you’ll instantly unlock the full, editable file formatted exactly as shown, ready for presentation, editing, or sharing.
No placeholders or hidden sections—this preview is a direct snapshot of the final deliverable, provided in the same professional layout.
Resources
Advanced Manufacturing Facilities
Jubilant Pharmova operates FDA-approved sterile and radiopharmaceutical plants in North America and India, supporting annual revenues tied to its pharma segment of about $230M in 2024; these facilities require >$50M–$100M capex to replicate and need specialized staff, creating a high barrier to entry.
Intellectual Property and Patents
Specialized Scientific Workforce
Jubilant Pharmova employs ~450 scientists, radiochemists, and engineers across India, the US, and Europe, specializing in nuclear medicine and complex chemistry; this workforce cut R&D cycle times by ~18% and supported a 2024 radiopharmaceutical revenue of INR 1.2 billion. Their expertise resolves manufacturing bottlenecks and fuels drug-discovery pipelines, so the firm invests ~6% of revenue in training and retention to sustain operational excellence.
Nuclear Pharmacy Infrastructure
Owning or exclusively accessing a network of nuclear pharmacies lets Jubilant Pharmova deliver short‑lived radiopharmaceuticals locally, capturing time-sensitive demand within isotope half‑lives (Tc‑99m half‑life 6 hrs). In 2025 Jubilant’s network supports same‑day delivery across X sites, reducing logistics loss and creating a durable competitive edge versus firms without localized presence.
- Enables same‑day reach within isotope decay window
- Reduces product loss, increases usable yield
- Strategic moat vs competitors lacking local sites
Financial Capital and Investment Capacity
Jubilant Pharmova’s strong financial capital—including a reported cash balance of INR 6.2 billion and committed credit lines of ~INR 10 billion as of FY2024 (ended Mar 31, 2024)—lets it fund capital-heavy manufacturing expansions and multi-year R&D programs tied to drug development cycles.
This liquidity also supports selective acquisitions; for example, the company completed small M&A deals in 2023-24 to broaden its specialty pharma portfolio and retain flexibility for larger strategic buys.
- Cash balance: INR 6.2 billion (FY2024)
- Committed credit lines: ~INR 10 billion
- R&D spend: ~6% of revenue (FY2024)
- Recent M&A activity: 2023–24 bolt-on deals
Radiopharma moat: FDA plants, broad patents, 450 specialists, strong liquidity
Key resources: FDA‑approved plants in NA/India, broad radiopharma patents (Ruby‑fill), ~450 specialised staff, nuclear pharmacy network for same‑day delivery, cash INR 6.2B and credit lines INR 10B, R&D ~INR 85Cr (FY2024).
| Resource | Key metric (FY2024/2025) |
|---|---|
| Plants | Capex to replicate: $50–100M |
| Patents | Protects radiopharma; supports INR 1120Cr revenue |
| Staff | ~450 specialists |
| Network | Same‑day delivery (Tc‑99m, 6h half‑life) |
| Liquidity | Cash INR 6.2B; credit INR 10B |
| R&D | INR 85Cr (~6% rev) |
Value Propositions
Integrated Radiopharmaceutical Solutions
Jubilant Pharmova offers an end-to-end radiopharmaceutical portfolio—from diagnostic PET/SPECT tracers to Lutetium-177 therapeutic isotopes—streamlining procurement for hospital nuclear medicine units and reducing supplier count by up to 40% in some contracts; in 2024 radiopharma sales grew ~18% to INR 1,320 crore (≈USD 160m). The bundled Ruby-fill delivery system improves dosing accuracy and cut dispensing errors by ~30% in published hospital pilots, boosting patient safety and throughput.
High Quality Contract Manufacturing Services
Jubilant Pharmova offers reliable, scalable contract manufacturing for complex sterile injectables, serving large pharma with facilities that supported ~USD 230m sterile revenue in FY2024 and >95% batch release success in 2024.
Clients gain reduced manufacturing risk and faster time-to-market via Jubilant’s strong regulatory record—12 successful US FDA/EMA audits since 2019—and ISO/GMP-certified processes that cut typical CMO onboarding by ~20%.
Specialized Allergy Diagnostic Portfolio
Jubilant Pharmova supplies a specialized allergy diagnostic portfolio of standardized and non-standardized allergenic extracts used in skin and in vitro tests, enabling personalized care for complex allergic profiles; in 2024 these products represented ~18% of the Pharma Services revenue, supporting over 2,500 specialist clinics worldwide and delivering batch-to-batch consistency with >98% lot stability, making them a preferred choice for allergy specialists globally.
End to End Research and Development Support
Through its CRDMO services, Jubilant Pharmova provides seamless end-to-end support from discovery to commercial scale, handling API development, clinical supply, and commercial manufacturing so biotech clients can focus on science; in 2024 CRDMO revenue contributed ~35% of Jubilant Pharmova’s reported ₹2,900 crore (≈$350M) revenue, showing scale and demand.
- Seamless discovery→commercial scale
- Handles API, clinical supply, commercial mfg
- 35% of 2024 revenue (~₹1,015 crore)
- Reduces client capex and technical risk
Global Regulatory Expertise and Compliance
Jubilant Pharmova’s regulatory teams secure approvals from FDA, EMA, MHRA and CDSCO, enabling 150+ product registrations across 60+ countries and cutting average market-entry time by ~20% versus peers (2024 internal data).
This reduces recall risk—company reported zero major regulatory recalls in 2023–24—and lowers time-to-revenue from new approvals, supporting steady CRO/API sales and 12% YoY export growth (FY2024).
- 150+ product registrations, 60+ countries
- ~20% faster market entry vs peers
- zero major recalls 2023–24
- 12% export revenue growth FY2024
Jubilant Pharmova consolidation boosts FY24 revenue to ₹2,900cr, radiopharma ₹1,320cr
Jubilant Pharmova bundles radiopharma, sterile injectables, CRDMO, and allergy diagnostics to cut supplier count ~40%, speed market entry ~20%, and drive FY2024 revenue ~₹2,900 crore (~$350M) with radiopharma ₹1,320 cr and CRDMO ~₹1,015 cr; >95% batch success, 150+ registrations across 60+ countries, zero major recalls 2023–24.
| Metric | 2024 |
|---|---|
| Total revenue | ₹2,900 cr |
| Radiopharma | ₹1,320 cr |
| CRDMO | ₹1,015 cr |
| Batch success | >95% |
| Registrations | 150+ |
Customer Relationships
Long Term Contractual Partnerships
Jubilant Pharmova secures long-term multi-year CMO/CRDMO agreements with large pharma and biotech firms, with contract revenues representing about 55% of FY2024 service income (₹2,430 crore), providing predictable cash flow and capacity planning.
These deals deploy dedicated project teams to hit milestone-linked payments and have enabled joint investments—three capacity expansions since 2022 totaling ~₹600 crore—aligning growth incentives and lowering unit costs over contract life.
Technical Support and Clinical Training
Jubilant Pharmova provides on-site technical support and clinical training for radiopharmaceuticals and delivery devices, conducting >1,200 hospital installations and training sessions in 2024 to ensure safe operation and regulatory compliance; this reduces user error by an estimated 35% and boosts repeat orders, contributing to the radiopharma segment’s 2024 revenue of INR 1,150 crore and strengthening brand loyalty.
Dedicated Key Account Management
Dedicated key account managers handle major hospital networks and nuclear medicine centers, coordinating supply to match demand volatility—Jubilant Pharmova reported supplying radiopharmaceuticals to 120+ hospital groups in 2024 with service-level fill rates averaging 96%, reducing stockouts and revenue loss. These managers also spot clinical needs and upsell adjacent diagnostics and logistics services, driving an estimated 8–12% incremental revenue per account in 2024.
Collaborative Development Interfaces
In Jubilant Pharmova’s CRDMO segment, client scientists co-work with Jubilant teams, enabling real-time data sharing and faster go/no-go decisions; in 2024 the CDMO revenue mix rose to ~52% of services, cutting average lead-time by ~18% versus industry peers.
- Partnership model: joint labs, shared dashboards
- Faster decisions: ~18% lead-time reduction (2024)
- Revenue impact: CDMO ~52% of services (2024)
Digital Engagement and Service Portals
By 2025, Jubilant Pharmova upgraded digital portals enabling customers to track 100% of orders, download regulatory docs (CTD dossiers, COAs) and request technical support 24/7, reducing average response time from 48h to 8h and cutting service costs by ~18% year-over-year.
These platforms collect structured feedback (NPS up to 62 in FY2024) and usage analytics, informing product improvements and raising on-time deliveries to 96%, boosting customer satisfaction and retention.
- Order tracking: 100% coverage
- Response time: 48h → 8h
- Service cost reduction: ~18%
- NPS: 62 (FY2024)
- On-time delivery: 96%
Jubilant Pharmova boosts CMO/CRDMO scale, cuts costs, and hits ₹1,150cr radiopharma
Jubilant Pharmova secures multi-year CMO/CRDMO contracts (55% of FY2024 service revenue, ₹2,430 crore), uses dedicated project teams and joint investments (~₹600 crore since 2022) to cut unit costs, and delivered radiopharma revenue of ₹1,150 crore in 2024 with 96% fill rates and NPS 62; digital portals cut response time 48h→8h and service costs ~18%.
| Metric | 2024/2025 |
|---|---|
| CMO/CRDMO share | 55% of services (₹2,430 cr) |
| Radiopharma rev | ₹1,150 cr |
| Joint capex since 2022 | ~₹600 cr |
| Fill rate | 96% |
| NPS | 62 |
| Response time | 48h→8h |
| Service cost cut | ~18% |
Channels
Direct Sales Force for Specialized Markets
A highly trained direct sales force targets hospital administrators, nuclear medicine physicians, and allergists, explaining radiopharmaceutical and immunotherapy value—driving adoption of high-margin proprietary drugs; in 2024 Jubilant Pharmova reported Specialty Pharmaceuticals revenue of INR 2.1 bn, with direct sales accounting for ~62% of specialty channel sales.
Proprietary and Partner Pharmacy Networks
Jubilant Pharmova ships radiopharmaceuticals via its proprietary network of 6 nuclear pharmacies plus 12 strategic partner sites, delivering doses same-day to hospitals and clinics; this localized channel is vital for short half-life isotopes (Tc-99m, F-18) that lose >50% activity in 6–8 hours, ensuring the right dose reaches the right patient at the right time and supporting ~42% of 2024 radiopharma revenue.
Global B2B Digital Marketing Platforms
Jubilant Pharmova targets procurement leads via global B2B digital platforms (ChemGuide, PharmaSources, Pharmalicensing) and LinkedIn campaigns, driving 62% of CRDMO (contract research, development & manufacturing organization) leads in 2024 and shortening sales cycles from 9 to 6 months. These channels showcase GMP facilities, API development and biologics scale-up services to buyers across 45+ countries, with digital lead generation contributing an estimated 28% of incremental CRDMO revenue in FY2024.
International Distributors and Agents
Jubilant Pharmova uses local distributors and agents in markets without direct offices, tapping regional know-how to manage logistics and regulatory compliance so the company keeps a global reach with a leaner headcount.
In 2024 distributors handled roughly 40% of export volumes and cut selling, general & admin (SG&A) per-market cost by an estimated 18% versus direct entry.
- ~40% export volume via partners (2024)
- ~18% lower SG&A per market
- Local regulatory handling reduces market entry time by months
Scientific Conferences and Trade Shows
Participation in major industry events like the Society of Nuclear Medicine and Molecular Imaging conference drives brand building for Jubilant Pharmova by enabling presentation of clinical data, new product launches, and partner networking; SNMMI 2024 drew ~6,000 attendees, offering access to leading nuclear medicine KOLs and procurement teams.
These events keep visibility with key opinion leaders and stakeholders, and typical conference ROI shows a 15–25% uplift in lead conversion within 6–12 months for pharma exhibitors.
- Present clinical data and launch products
- Network with partners and KOLs (SNMMI 2024 ≈6,000 attendees)
- Boost lead conversion 15–25% post-event
Omnichannel lift: Direct sales, nukes, digital & distributors drive +28% CRDMO revenue
Direct sales (62% of specialty sales) and 6 nuclear pharmacies (42% radiopharma rev) deliver same‑day doses; digital B2B and LinkedIn shorten CRDMO sales from 9→6 months, generating ~28% incremental CRDMO revenue; distributors handle ~40% exports and cut SG&A per market ~18%; conferences (SNMMI 2024, ~6,000 attendees) lift lead conversion 15–25%.
| Channel | 2024 metric |
|---|---|
| Direct sales | 62% specialty sales (INR 2.1bn) |
| Nuclear pharmacies | 6 sites; 42% radiopharma rev |
| Digital B2B | CRDMO leads +28% rev; sales 9→6 mo |
| Distributors | 40% export vol; −18% SG&A |
| Conferences | SNMMI 2024 ≈6,000; +15–25% conversion |
Customer Segments
Large Global Pharmaceutical Companies
Large global pharmaceutical companies use Jubilant Pharmova’s CMO and CRDMO services to outsource sterile injectable manufacturing and drug discovery, valuing scale, GMP quality, and regulatory compliance; in FY2024 Jubilant’s Pharma Services reported ₹2,340 crore revenue, reflecting steady, high-volume contracts. These partners drive long-term, recurring revenue: contract tenures often exceed 5 years and single-client contributions can represent 15–25% of segment sales.
Nuclear Medicine Centers and Hospitals
Nuclear medicine centers and hospitals rely on Jubilant Pharmova for steady supplies of diagnostic and therapeutic radiopharmaceuticals, including Tc-99m and Lu-177, plus delivery systems and cold kits; global nuclear medicine procedures rose ~3.5% in 2024 to ~17.2 million, driving predictable recurring orders.
Specialized Allergists and Immunologists
Specialized allergists and immunologists need precise allergenic extracts for diagnosis and treatment, and Jubilant Pharmova’s portfolio—covering over 120 extracts as of 2025—enables tailored immunotherapy regimens and skin testing.
This segment shows high brand loyalty with repeat orders: clinic-level reorder rates exceed 70% and account for roughly 18% of Jubilant’s diagnostics revenue in FY2024, providing stable, predictable demand.
Emerging Biotechnology Firms
Small- to mid-sized biotech firms lacking manufacturing and clinical-scale R&D rely on Jubilant Pharmova’s CRDMO (contract research, development and manufacturing organization) services to scale drug candidates; this segment drove ~22% of Jubilant Pharmova’s 2024 service revenue and commands higher gross margins (est. 28–35%).
- Labs → clinic: fills infrastructure gap
- High-margin services: ~28–35% gross margin
- Revenue impact: ~22% of 2024 service sales
- Growth driver: rising biotech deal flow in 2023–24
Government and Public Health Agencies
Government and public health agencies—national health ministries and government hospitals—buy bulk essential medicines and diagnostics via tenders and multi-year contracts, representing ~30–40% of Jubilant Pharmova’s institutional sales in FY2024 (company filings) and enabling steady cash flow and scale.
- Large tenders: multi-year contracts, predictable revenue
- Market reach: expands public-sector penetration, supports national programs
- Impact: aligns with public health goals, boosts volume-driven margins
Diverse FY2024 Revenue Drivers: CMOs, Nuclear Medicine, Allergists, Biotech & Tenders
Global pharma CMOs (long-term contracts; client share 15–25%), nuclear medicine centers (17.2M procedures in 2024), allergists (120+ extracts; clinic reorder >70%), small–mid biotech (22% of 2024 service revenue; gross margin 28–35%), and government tenders (30–40% institutional sales in FY2024).
| Segment | Key metric | FY2024/2024 |
|---|---|---|
| Global pharma CMO | Client share | 15–25% |
| Nuclear medicine | Procedures | 17.2M |
| Allergists | Extracts / reorder | 120+ / >70% |
| SMB biotech | Service revenue / margin | 22% / 28–35% |
| Govt tenders | Institutional sales | 30–40% |
Cost Structure
Research and Development Expenditures
Jubilant Pharmova allocates roughly 12–14% of FY2024 revenue (about INR 420–490 crore on revenue ~INR 3,500 crore) to R&D, funding drug-discovery, device improvements, clinical trials, lab supplies, and senior researcher salaries.
Manufacturing and Operational Overheads
Manufacturing and operational overheads form a large share of Jubilant Pharmova’s costs—energy, specialized equipment upkeep, and skilled technician payrolls; in FY2024 consolidated manufacturing & other expenses were roughly INR 1,120 crore, reflecting 28% of operating costs. Efficient plant utilization (target >80% in CMO) and energy optimization can improve margins given capital‑intensive facilities and high fixed costs.
Regulatory Compliance and Quality Assurance
Regulatory compliance and quality assurance cost Jubilant Pharmova about INR 1.2–1.6 billion annually (2024), covering internal QC labs, external GMP audits, and regulatory filings across US, EU, and India; continuous monitoring and documentation drive ~4–6% of Opex in pharma services. Compliance is non-negotiable—these expenses protect manufacturing licenses and mitigate recall, litigation, and market-access losses.
Raw Material and Isotope Procurement
The cost of sourcing high-purity chemicals and medical isotopes is a major variable expense for Jubilant Pharmova, with isotope procurement prices swinging up to 20–30% year-on-year during 2022–2024 due to supply tightness.
Maintaining buffer inventory and dual-sourcing raised working-capital needs by an estimated $10–15M annually but cut stockout risk and ensured continuity for radiopharma contracts.
- Isotope price volatility: ±20–30% (2022–24)
- Added working capital for resilience: $10–15M/yr
- Dual-sourcing reduces stockout risk, raises upfront cost
Sales Marketing and Administrative Costs
FY24 Costs: INR 3,850–4,050cr; R&D 12–14%, Isotope Spend ±20–30%
Total FY2024 costs: ~INR 3,850–4,050 crore; R&D 12–14% (~INR 420–490cr); Manufacturing & other Opex ~INR 1,120cr; SG&A ~INR 1,120cr; Compliance ~INR 120–160cr; isotope spend volatile ±20–30%, added working capital $10–15M/yr.
| Item | FY2024 |
|---|---|
| Total costs | INR 3,850–4,050cr |
| R&D | INR 420–490cr (12–14%) |
| Manufacturing | INR 1,120cr |
| SG&A | INR 1,120cr |
| Compliance | INR 120–160cr |
| Isotope volatility | ±20–30% |
| Extra working capital | $10–15M/yr |
Revenue Streams
Sales of Radiopharmaceutical Products
Sales of diagnostic and therapeutic radiopharmaceuticals form Jubilant Pharmova’s main revenue, covering radioactive doses and delivery systems like the Ruby-fill generator; FY2024 radiopharma sales were about INR 1,020 crore (≈USD 124m), up ~12% y/y. Demand is driven by rising nuclear medicine procedures—global PET/CT scans grew ~6% in 2023—boosting volumes and ASPs for generators and ready-to-use doses.
Contract Manufacturing Service Fees
Revenue comes from service agreements to manufacture sterile injectables and other dosage forms for pharma clients, with fees tied to production volume and process complexity; Jubilant Pharmova reported contract manufacturing revenue of INR 2,180 crore in FY2024, reflecting ~35% of its Pharma segment sales. Long-term contracts yield predictable cash flows—multi-year agreements often lock utilization above 80%, reducing revenue volatility.
Allergy Immunotherapy Product Sales
The company sells diagnostic skin test antigens and therapeutic allergy vaccines to specialists, generating recurring product sales; global allergy prevalence rose to ~30% of adults by 2024, supporting steady demand. Proprietary extracts give Jubilant Pharmova pricing power—allergy franchise revenue was reported at INR 1.2 bn in FY2024, up ~8% year-on-year, indicating stable, growing income.
Drug Discovery and CRDMO Revenue
Jubilant Pharmova earns revenue by offering drug discovery and contract research, development and manufacturing organization (CRDMO) services—medicinal chemistry, biology, and preclinical work—to biotech and pharma clients, receiving upfront service fees plus milestone-based payments; in FY2024 India segment CRDMO-like services contributed roughly 28% of consolidated revenue (~INR 1,020 crore reported in FY2024).
- Upfront service fees for projects
- Milestone payments tied to development stages
- Fee-for-service medicinal chemistry and biology
- Preclinical program retainers and scale-up fees
- FY2024 contribution ≈28%, ~INR 1,020 crore
Licensing and Milestone Payments
FY24 Revenue Mix: Radiopharma ₹1,020cr, Injectables ₹2,180cr, CRDMO ₹1,020cr, Licensing $45–55m
Core revenues: radiopharma sales INR 1,020 crore (FY2024), CMFG/sterile injectables INR 2,180 crore (FY2024, ~35% Pharma), allergy INR 12 crore (FY2024), CRDMO ~INR 1,020 crore (FY2024, 28%), licensing receipts USD 45–55m (2024).
| Stream | FY2024 |
|---|---|
| Radiopharma | INR 1,020 cr |
| CMFG/Injectables | INR 2,180 cr |
| Allergy | INR 12 cr |
| CRDMO | INR 1,020 cr |
| Licensing | USD 45–55 m |